Cellular, Molecular and Clinical Determinants of Bone Strength in in Vivo and Human Models of GH Excess.

Cellular, Molecular and Clinical Determinants of Bone Strength in in Vivo and Human Models of GH Excess. Cross-sectional and Prospective Study

Prospective observational clinical, molecular, translational study aimed at identifying the main determinants and predictive factors of fragility fracture risck in acromegaly patients

Inclusion Criteria:

• confirmed diagnosis of acromegaly
• availability to carry out outpatient checks
• ability to provide informed consent

Exclusion Criteria:

• Pregnancy
• use of glucocorticoids (except those in use for replacement therapy)
• alcohol abuse
• exacerbation of chronic disease
• serious comorbidities (renal or hepatic failure, heart attack, stroke)
• terminally ill, prolonged immobilization (>1 week)
• clinically evident fracture within the previous six months
• any other cause of secondary osteoporosis within the last five years
• any prolonged treatment with drugs with documented influence on bone metabolism during the previous 12 months, including treatment with antiresorptive or anabolic compounds for osteoporosis.